

SAFETY DATA SHEET



Mometasone Suspension Formulation



Version 2.14 Revision Date: 04/09/2021 SDS Number: 23586-00017 Date of last issue: 10/16/2020
Date of first issue: 10/21/2014

SECTION 1. IDENTIFICATION

Product name : Mometasone Suspension Formulation
Other means of identification : No data available

Manufacturer or supplier's details

Company name of supplier : Organon & Co.
Address : 30 Hudson Street, 33rd floor
Jersey City, New Jersey, U.S.A 07302
Telephone : 551-430-6000
Emergency telephone : 215-631-6999
E-mail address : EHSSTEWARD@organon.com

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical
Restrictions on use : Not applicable

SECTION 2. HAZARDS IDENTIFICATION

GHS classification in accordance with the Hazardous Products Regulations

Not a hazardous substance or mixture.

GHS label elements

Not a hazardous substance or mixture.

Other hazards

None known.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	Common Name/Synonym	CAS-No.	Concentration (% w/w)
Glycerine	1,2,3-Propanetriol	56-81-5	$\geq 1 - < 5$ *
Cellulose	No data available	9004-34-6	$\geq 1 - < 5$ *
Mometasone	No data available	83919-23-7	$\geq 0 - < 0.1$ *

* Actual concentration or concentration range is withheld as a trade secret

SECTION 4. FIRST AID MEASURES

If inhaled : If inhaled, remove to fresh air.
Get medical attention if symptoms occur.
In case of skin contact : Wash with water and soap as a precaution.
Get medical attention if symptoms occur.
In case of eye contact : Flush eyes with water as a precaution.
Get medical attention if irritation develops and persists.

Mometasone Suspension Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10/16/2020
2.14	04/09/2021	23586-00017	Date of first issue: 10/21/2014

If swallowed	:	If swallowed, DO NOT induce vomiting. Get medical attention if symptoms occur. Rinse mouth thoroughly with water.
Most important symptoms and effects, both acute and delayed	:	None known.
Protection of first-aiders	:	No special precautions are necessary for first aid responders.
Notes to physician	:	Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media	:	Water spray Alcohol-resistant foam Carbon dioxide (CO ₂) Dry chemical
Unsuitable extinguishing media	:	None known.
Specific hazards during fire fighting	:	Exposure to combustion products may be a hazard to health.
Hazardous combustion products	:	Carbon oxides
Specific extinguishing methods	:	Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.
Special protective equipment for fire-fighters	:	Wear self-contained breathing apparatus for firefighting if necessary. Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures	:	Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
Environmental precautions	:	Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Prevent spreading over a wide area (e.g., by containment or oil barriers). Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.
Methods and materials for containment and cleaning up	:	Soak up with inert absorbent material. For large spills, provide diking or other appropriate containment to keep material from spreading. If diked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absorbent. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items

SAFETY DATA SHEET



Mometasone Suspension Formulation



Version 2.14 Revision Date: 04/09/2021 SDS Number: 23586-00017 Date of last issue: 10/16/2020
Date of first issue: 10/21/2014

employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

- Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
- Local/Total ventilation : Use only with adequate ventilation.
- Advice on safe handling : Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Take care to prevent spills, waste and minimize release to the environment.
- Conditions for safe storage : Keep in properly labeled containers.
Store in accordance with the particular national regulations.
- Materials to avoid : Do not store with the following product types:
Strong oxidizing agents

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Glycerine	56-81-5	TWA (Mist)	10 mg/m ³	CA AB OEL
		TWA (Mist)	10 mg/m ³	CA BC OEL
		TWA (Respirable mist)	3 mg/m ³	CA BC OEL
		TWAEV (Mist)	10 mg/m ³	CA QC OEL
Cellulose	9004-34-6	TWA	10 mg/m ³	CA AB OEL
		TWA (Total dust)	10 mg/m ³	CA BC OEL
		TWA (respirable dust fraction)	3 mg/m ³	CA BC OEL
		TWAEV (total dust)	10 mg/m ³	CA QC OEL
		TWA	10 mg/m ³	ACGIH
Mometasone	83919-23-7	TWA	1 µg/m ³ (OEB 4)	Internal
	Further information: Skin			
		Wipe limit	10 µg/100 cm ²	Internal

- Engineering measures** : All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.
Essentially no open handling permitted.
Use closed processing systems or containment technologies.
If handled in a laboratory, use a properly designed biosafety

Mometasone Suspension Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10/16/2020
2.14	04/09/2021	23586-00017	Date of first issue: 10/21/2014

cabinet, fume hood, or other containment device if the potential exists for aerosolization. If this potential does not exist, handle over lined trays or benchtops.

Personal protective equipment

- Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
- Filter type : Combined particulates and organic vapor type
- Hand protection
- Material : Chemical-resistant gloves
- Remarks : Consider double gloving.
- Eye protection : Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
- Skin and body protection : Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.
- Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

- Appearance : liquid
- Color : white to off-white, opaque
- Odor : odorless
- Odor Threshold : No data available
- pH : 4.3 - 4.9
- Melting point/freezing point : No data available
- Initial boiling point and boiling range : No data available
- Flash point : No data available

Mometasone Suspension Formulation

Version 2.14 Revision Date: 04/09/2021 SDS Number: 23586-00017 Date of last issue: 10/16/2020
Date of first issue: 10/21/2014

Evaporation rate	:	No data available
Flammability (solid, gas)	:	Not applicable
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapor pressure	:	No data available
Relative vapor density	:	No data available
Relative density	:	No data available
Density	:	1 g/cm ³
Solubility(ies)	:	
Water solubility	:	soluble
Partition coefficient: n-octanol/water	:	Not applicable
Autoignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity	:	
Viscosity, kinematic	:	No data available
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Molecular weight	:	Not applicable
Particle size	:	Not applicable

SECTION 10. STABILITY AND REACTIVITY

Reactivity	:	Not classified as a reactivity hazard.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reactions	:	Can react with strong oxidizing agents.
Conditions to avoid	:	None known.
Incompatible materials	:	Oxidizing agents
Hazardous decomposition products	:	No hazardous decomposition products are known.

Mometasone Suspension Formulation

Version Revision Date: SDS Number: Date of last issue: 10/16/2020
2.14 04/09/2021 23586-00017 Date of first issue: 10/21/2014

SECTION 11. TOXICOLOGICAL INFORMATION**Information on likely routes of exposure**

Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

Not classified based on available information.

Components:**Glycerine:**

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg
Acute dermal toxicity : LD50 (Guinea pig): > 5,000 mg/kg

Cellulose:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg
Acute inhalation toxicity : LC50 (Rat): > 5.8 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist
Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

Mometasone:

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg
LD50 (Mouse): > 2,000 mg/kg
Acute inhalation toxicity : LC50 (Rat): > 3.3 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist
Remarks: No mortality observed at this dose.
LC50 (Mouse): > 3.2 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist

Acute toxicity (other routes of administration) : LD50 (Rat): 300 mg/kg
Application Route: Subcutaneous
Symptoms: Breathing difficulties

Skin corrosion/irritation

Not classified based on available information.

Components:**Glycerine:**

Species : Rabbit
Result : No skin irritation

Mometasone Suspension Formulation

Version 2.14 Revision Date: 04/09/2021 SDS Number: 23586-00017 Date of last issue: 10/16/2020
Date of first issue: 10/21/2014

Mometasone:

Species : Rabbit
Result : No skin irritation

Serious eye damage/eye irritation

Not classified based on available information.

Components:**Glycerine:**

Species : Rabbit
Result : No eye irritation

Mometasone:

Species : Rabbit
Result : No eye irritation

Respiratory or skin sensitization**Skin sensitization**

Not classified based on available information.

Respiratory sensitization

Not classified based on available information.

Components:**Mometasone:**

Test Type : Maximization Test
Routes of exposure : Dermal
Species : Guinea pig
Assessment : Does not cause skin sensitization.
Result : negative
Remarks : The results of a test on guinea pigs showed this substance to be a weak skin sensitizer.

Germ cell mutagenicity

Not classified based on available information.

Components:**Glycerine:**

Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test
Result: negative

Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: Chromosome aberration test in vitro
Result: negative

Test Type: DNA damage and repair, unscheduled DNA syn-

Mometasone Suspension Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10/16/2020
2.14	04/09/2021	23586-00017	Date of first issue: 10/21/2014

thesis in mammalian cells (in vitro)

Result: negative

Cellulose:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: In vitro mammalian cell gene mutation test

Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
Species: Mouse
Application Route: Ingestion
Result: negative

Mometasone:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: Chromosomal aberration

Test system: Chinese hamster lung cells

Result: negative

Test Type: Chromosomal aberration

Test system: Chinese hamster ovary cells

Result: positive

Test Type: Mouse Lymphoma

Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test
Species: Mouse
Application Route: Oral
Result: negative

Test Type: Chromosomal aberration

Species: Rat

Cell type: Bone marrow

Result: negative

Test Type: unscheduled DNA synthesis assay

Species: Rat

Cell type: Liver cells

Result: negative

Germ cell mutagenicity - Assessment : Weight of evidence does not support classification as a germ cell mutagen.

Carcinogenicity

Not classified based on available information.

Mometasone Suspension Formulation

Version 2.14 Revision Date: 04/09/2021 SDS Number: 23586-00017 Date of last issue: 10/16/2020
Date of first issue: 10/21/2014

Components:**Glycerine:**

Species : Rat
Application Route : Ingestion
Exposure time : 2 Years
Result : negative

Cellulose:

Species : Rat
Application Route : Ingestion
Exposure time : 72 weeks
Result : negative

Mometasone:

Species : Rat
Application Route : Inhalation
Exposure time : 2 Years
Dose : 0.067 mg/kg body weight
Result : negative

Species : Mouse
Application Route : Inhalation
Exposure time : 19 Months
Dose : 0.160 mg/kg body weight
Result : negative

Reproductive toxicity

Not classified based on available information.

Components:**Glycerine:**

Effects on fertility : Test Type: Two-generation reproduction toxicity study
Species: Rat
Application Route: Ingestion
Result: negative

Effects on fetal development : Test Type: Embryo-fetal development
Species: Rat
Application Route: Ingestion
Result: negative

Cellulose:

Effects on fertility : Test Type: One-generation reproduction toxicity study
Species: Rat
Application Route: Ingestion
Result: negative

Effects on fetal development : Test Type: Fertility/early embryonic development
Species: Rat
Application Route: Ingestion

Mometasone Suspension Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10/16/2020
2.14	04/09/2021	23586-00017	Date of first issue: 10/21/2014

Result: negative

Mometasone:

Effects on fertility : Test Type: Fertility
 Species: Rat
 Application Route: Subcutaneous
 Fertility: NOAEL: 0.015 mg/kg body weight
 Symptoms: Reduced embryonic survival, Reduced fetal weight.
 Result: No effects on fertility., Effect on reproduction capacity.

Effects on fetal development : Test Type: Embryo-fetal development
 Species: Mouse
 Application Route: Subcutaneous
 Embryo-fetal toxicity.: LOAEL: 0.06 mg/kg body weight
 Result: Embryotoxic effects., Teratogenicity and developmental toxicity

Test Type: Embryo-fetal development
 Species: Rat
 Application Route: Dermal
 Embryo-fetal toxicity.: LOAEL: 0.3 mg/kg body weight
 Result: Embryo-fetal toxicity.

Test Type: Embryo-fetal development
 Species: Rabbit
 Application Route: Dermal
 Embryo-fetal toxicity.: LOAEL: 0.15 mg/kg body weight
 Result: Embryo-fetal toxicity., Malformations were observed.

Test Type: Embryo-fetal development
 Species: Rat
 Application Route: Subcutaneous
 Embryo-fetal toxicity.: LOAEL: 0.15 mg/kg body weight
 Result: Effects on newborn.

Test Type: Embryo-fetal development
 Species: Rabbit
 Application Route: Oral
 Embryo-fetal toxicity.: LOAEL: 0.7 mg/kg body weight
 Result: Embryo-fetal toxicity., Malformations were observed.

Reproductive toxicity - Assessment : Clear evidence of adverse effects on development, based on animal experiments., Some evidence of adverse effects on sexual function and fertility, based on animal experiments.

STOT-single exposure

Not classified based on available information.

Components:**Mometasone:**

Remarks : Based on available data, the classification criteria are not met.

Mometasone Suspension Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10/16/2020
2.14	04/09/2021	23586-00017	Date of first issue: 10/21/2014

STOT-repeated exposure

Not classified based on available information.

Components:**Mometasone:**

Routes of exposure	:	inhalation (dust/mist/fume)
Target Organs	:	Immune system, Liver, Kidney, Skin
Assessment	:	May cause damage to organs through prolonged or repeated exposure.

Repeated dose toxicity**Components:****Glycerine:**

Species	:	Rat
NOAEL	:	0.167 mg/l
LOAEL	:	0.622 mg/l
Application Route	:	inhalation (dust/mist/fume)
Exposure time	:	13 Weeks

Species	:	Rat
NOAEL	:	8,000 - 10,000 mg/kg
Application Route	:	Ingestion
Exposure time	:	2 y

Species	:	Rabbit
NOAEL	:	5,040 mg/kg
Application Route	:	Skin contact
Exposure time	:	45 Weeks

Cellulose:

Species	:	Rat
NOAEL	:	>= 9,000 mg/kg
Application Route	:	Ingestion
Exposure time	:	90 Days

Mometasone:

Species	:	Rat
NOAEL	:	0.005 mg/kg
LOAEL	:	0.3 mg/kg
Application Route	:	Oral
Exposure time	:	30 d
Target Organs	:	Lymph nodes, Liver, Adrenal gland, Skin, thymus gland

Species	:	Dog
LOAEL	:	0.5 mg/kg
Application Route	:	Oral
Exposure time	:	30 d
Target Organs	:	Lymph nodes, Liver, Adrenal gland, Skin, thymus gland

Species	:	Rat
---------	---	-----

Mometasone Suspension Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10/16/2020
2.14	04/09/2021	23586-00017	Date of first issue: 10/21/2014

NOAEL	:	0.00013 mg/l
Application Route	:	inhalation (dust/mist/fume)
Exposure time	:	90 d
Target Organs	:	Adrenal gland, Lungs, Lymph nodes, spleen, Bone marrow, Kidney, Liver, thymus gland

Species	:	Dog
NOAEL	:	0.0005 mg/l
Application Route	:	inhalation (dust/mist/fume)
Exposure time	:	90 d
Target Organs	:	Adrenal gland, Lungs, Lymph nodes, spleen, Bone marrow, Kidney, thymus gland, Liver

Aspiration toxicity

Not classified based on available information.

Components:

Mometasone:

Not applicable

Experience with human exposure

Components:

Mometasone:

Inhalation	:	Symptoms: allergic rhinitis, Headache, pharyngitis, upper respiratory tract infection, sinusitis, oral candidiasis, Back pain, musculoskeletal pain, immune system effects, indigestion
Skin contact	:	Symptoms: Dermatitis, Itching

Further information

Components:

Mometasone:

Remarks	:	Dermal absorption possible
---------	---	----------------------------

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Glycerine:

Toxicity to fish	:	LC50 (Oncorhynchus mykiss (rainbow trout)): 54,000 mg/l Exposure time: 96 h
Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Daphnia magna (Water flea)): 1,955 mg/l Exposure time: 48 h
Toxicity to microorganisms	:	NOEC (Pseudomonas putida): > 10,000 mg/l Exposure time: 16 h Method: DIN 38 412 Part 8

Mometasone Suspension Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10/16/2020
2.14	04/09/2021	23586-00017	Date of first issue: 10/21/2014

Cellulose:

Toxicity to fish : LC50 (*Oryzias latipes* (Japanese medaka)): > 100 mg/l
 Exposure time: 48 h
 Remarks: Based on data from similar materials

Mometasone:

Toxicity to fish : LC50 (*Menidia beryllina* (Silverside)): 0.11 mg/l
 Exposure time: 96 h
 Remarks: No toxicity at the limit of solubility.

LC50 (*Cyprinodon variegatus* (sheepshead minnow)): > 5 mg/l
 Exposure time: 7 d
 Remarks: No toxicity at the limit of solubility.

Toxicity to daphnia and other aquatic invertebrates : EC50 (*Daphnia magna* (Water flea)): > 5 mg/l
 Exposure time: 48 h
 Method: OECD Test Guideline 202
 Remarks: No toxicity at the limit of solubility.

EC50 (*Americamysis*): > 5 mg/l
 Exposure time: 96 h
 Method: US-EPA OPPTS 850.1035
 Remarks: No toxicity at the limit of solubility.

Toxicity to algae/aquatic plants : EC50 (*Pseudokirchneriella subcapitata* (green algae)): > 3.2 mg/l
 Exposure time: 72 h
 Method: OECD Test Guideline 201
 Remarks: No toxicity at the limit of solubility.

Toxicity to fish (Chronic toxicity) : NOEC (*Pimephales promelas* (fathead minnow)): 0.00014 mg/l
 Exposure time: 32 d
 Method: OECD Test Guideline 210

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (*Daphnia magna* (Water flea)): 0.34 mg/l
 Exposure time: 21 d
 Method: OECD Test Guideline 211
 Remarks: No toxicity at the limit of solubility.

Toxicity to microorganisms : EC50: > 1,000 mg/l
 Exposure time: 3 h
 Test Type: Respiration inhibition
 Method: OECD Test Guideline 209
 Remarks: No toxicity at the limit of solubility.

NOEC: 1,000 mg/l
 Exposure time: 3 h
 Test Type: Respiration inhibition
 Method: OECD Test Guideline 209
 Remarks: No toxicity at the limit of solubility.

Mometasone Suspension Formulation

Version 2.14 Revision Date: 04/09/2021 SDS Number: 23586-00017 Date of last issue: 10/16/2020
Date of first issue: 10/21/2014

Persistence and degradability**Components:****Glycerine:**

Biodegradability : Result: Readily biodegradable.
Biodegradation: 92 %
Exposure time: 30 d
Method: OECD Test Guideline 301D

Cellulose:

Biodegradability : Result: Readily biodegradable.

Mometasone:

Biodegradability : Result: Not readily biodegradable.
Biodegradation: 50 %
Exposure time: 28 d
Method: OECD Test Guideline 314

Stability in water : Hydrolysis: 50 %(12 d)
Method: OECD Test Guideline 111

Bioaccumulative potential**Components:****Glycerine:**

Partition coefficient: n-octanol/water : log Pow: -1.75

Mometasone:

Bioaccumulation : Species: Lepomis macrochirus (Bluegill sunfish)
Bioconcentration factor (BCF): 107.1
Method: OECD Test Guideline 305

Partition coefficient: n-octanol/water : log Pow: 4.68

Mobility in soil**Components:****Mometasone:**

Distribution among environmental compartments : log Koc: 4.02

Other adverse effects

No data available

SECTION 13. DISPOSAL CONSIDERATIONS**Disposal methods**

Waste from residues : Dispose of in accordance with local regulations.
Contaminated packaging : Empty containers should be taken to an approved waste

Mometasone Suspension Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10/16/2020
2.14	04/09/2021	23586-00017	Date of first issue: 10/21/2014

handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION**International Regulations****UNRTDG**

UN number : UN 3082
 Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S.
 (Mometasone, Benzalkonium chloride)
 Class : 9
 Packing group : III
 Labels : 9

IATA-DGR

UN/ID No. : UN 3082
 Proper shipping name : Environmentally hazardous substance, liquid, n.o.s.
 (Mometasone, Benzalkonium chloride)
 Class : 9
 Packing group : III
 Labels : Miscellaneous
 Packing instruction (cargo aircraft) : 964
 Packing instruction (passenger aircraft) : 964
 Environmentally hazardous : yes

IMDG-Code

UN number : UN 3082
 Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S.
 (Mometasone, Benzalkonium chloride)
 Class : 9
 Packing group : III
 Labels : 9
 EmS Code : F-A, S-F
 Marine pollutant : yes

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Domestic regulation**TDG**

UN number : UN 3082
 Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S.
 (Mometasone, Benzalkonium chloride)
 Class : 9
 Packing group : III
 Labels : 9
 ERG Code : 171
 Marine pollutant : yes(Mometasone, Benzalkonium chloride)

Mometasone Suspension Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10/16/2020
2.14	04/09/2021	23586-00017	Date of first issue: 10/21/2014

Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

SECTION 15. REGULATORY INFORMATION**The ingredients of this product are reported in the following inventories:**

AICS	:	not determined
DSL	:	not determined
IECSC	:	not determined

SECTION 16. OTHER INFORMATION**Full text of other abbreviations**

ACGIH	:	USA. ACGIH Threshold Limit Values (TLV)
CA AB OEL	:	Canada. Alberta, Occupational Health and Safety Code (table 2: OEL)
CA BC OEL	:	Canada. British Columbia OEL
CA QC OEL	:	Québec. Regulation respecting occupational health and safety, Schedule 1, Part 1: Permissible exposure values for airborne contaminants
ACGIH / TWA	:	8-hour, time-weighted average
CA AB OEL / TWA	:	8-hour Occupational exposure limit
CA BC OEL / TWA	:	8-hour time weighted average
CA QC OEL / TWA EV	:	Time-weighted average exposure value

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances

SAFETY DATA SHEET



Mometasone Suspension Formulation



Version	Revision Date:	SDS Number:	Date of last issue: 10/16/2020
2.14	04/09/2021	23586-00017	Date of first issue: 10/21/2014

es; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

Sources of key data used to compile the Material Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Revision Date : 04/09/2021
Date format : mm/dd/yyyy

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

CA / Z8